Cal Warriner of the Mass Torts Unit of Searcy Denney will be speaking this week at the Plaintiff Forum on Pharmaceutical Litigation: Transvaginal Mesh, Actos and Orthopedic Devices. The conference will be held on Friday of this week (October 5, 2012) at Le Méridien in Philadelphia, Pennsylvania. Cal will be […]
Category: Actos
A federal judge has scheduled proceedings for the first of two test trials in the Actos litigation. The bellwether trials, as they are known, are set for November 3, 2014, and January 12, 2015 in the multidistrict litigation consolidated in the U.S. District Court for the Western District of Louisiana. […]
According to a study published June 11, the users of Actos (pioglitazone) or Avandia (rosiglitazone) may face an increased risk of developing macular edema. Published in the Archives of Internal Medicine, British researchers collected data on more than 100,000 patients with type 2 diabetes who were enrolled in the British […]
A recently unsealed complaint filed by whistleblower Helen Ge reveals that over four years, Takeda Pharmaceuticals failed to report to the FDA congestive heart failure cases in patients taking Actos. Takeda manufactures the Type II diabetes drug Actos. Actos is the third in a long line of failed Type II […]
One of the first cases involving a plaintiff who developed bladder cancer as a result of taking the diabetes drug, Actos was filed by Mass Tort Attorneys of Searcy Denney in the Southern District of Florida, Miami Division. This case involves a married executive who lives in the Miami area […]
On December 29, 2011 the Judicial Panel on Multidistrict Litigation (JPML) entered an Order consolidating all pending federal Actos bladder cancer lawsuits. Actos, generically known as pioglitazone, is a prescription medication manufactured by Takeda Pharmaceuticals and used to treat Type 2 diabetes, often referred to as adult onset diabetes. The […]
